01重点学术场次Priority Sessions13 场
本专题的重点场次包含 Hot Line、LBCS、New ESC Guidelines、Ask the Trialists、Guidelines in Practice、Great Debates 等。
抗栓策略5 场Hot Line 3
Hot Line
HOT LINE 3(全球首发专场)
HOT LINE 3
LIBREXIA ACS:近期 ACS 后使用 milvexian
LIBREXIA ACS: Milvexian after recent ACS
PREMIUM:STEMI 直接 PCI 时省略阿司匹林
PREMIUM: Aspirin Omission at the Time of Primary PCI in STEMI
SWITCH SWEDEHEART——ACS 患者从替格瑞洛换用普拉格雷
SWITCH SWEDEHEART - Switching from ticagrelor to prasugrel in patients with ACS
A-CLOSE:高危 PCI 术后氯吡格雷对比延长双联抗血小板治疗
A-CLOSE: Clopidogrel vs Extended DAPT after High-Risk PCI
EPIDAURUS 试验
EPIDAURUS
Hot Line
HOT LINE 11(全球首发专场)
HOT LINE 11
EVAOLD:老年患者再灌注策略评估
EVAOLD: Evaluation of reperfusion stategies in elderly patients
ISOLEDS:远端左主干分叉病变 PCI 中 IVUS 对比 OCT 引导
ISOLEDS: IVUS vs OCT Guidance for PCI of Distal Left Main Bifurcation Lesions
CorCal 研究:ASCVD 一级预防中合并队列方程对比冠脉钙化积分
CorCal Study: Pooled Cohort Equations versus Coronary Artery Calcium Score in ASCVD Primary Prevention
CoCAP 研究:CABG 后 ACS 患者双联抗血小板或单用阿司匹林的桥血管通畅率
CoCAP Study: Graft Patency in ACS patients treated with DAPT or single Aspirin after CABG
Hot Line
HOT LINE 7(全球首发专场)
HOT LINE 7
POPular ACE TAVI 试验:TAVI 后常规还是选择性给予鱼精蛋白?
The POPular ACE TAVI trial: routine or selective protamine administration after TAVI?
TAVI-PCI:经导管主动脉瓣植入与经皮冠状动脉介入
TAVI PCI: Transcatheter Aortic Valve Implantation and Percutaneous Coronary Intervention
TRIC-I-HF:心力衰竭中的三尖瓣干预
TRIC-I-HF: Tricuspid Intervention in Heart Failure
ACASA-TAVI:TAVI 术后抗栓治疗
ACASA-TAVI : Antithrombotic therapy after TAVI
NOTION-4:TAVI 后亚临床瓣叶血栓
NOTION-4. Subclinical leaflet thrombosis after TAVI.
Great Debates
焦点辩论:慢性冠脉综合征患者应否以氯吡格雷替代阿司匹林
Great Debate: clopidogrel should replace aspirin for patients with chronic coronary syndromes
慢性冠脉综合征患者应以氯吡格雷替代阿司匹林
Clopidogrel should replace aspirin for patients with chronic coronary syndromes
正方Daniele GiacoppoAOU Policlinico反方Bianca RoccaLUM University评论员Stefan JamesUppsala University
LBCS
晚期临床试验:急性心肌梗死管理优化
Late-Breaking Clinical Trials: optimising management of acute myocardial infarction
EnVast 血栓抽吸装置作为 STEMI 的辅助再灌注手段
EnVast thrombectomy device as adjunctive reperfusion modality in ST-segment elevation myocardial infarction
STEMI 合并多支血管病变中生理学指导的分期完全血运重建的时间依赖性效应:多中心开放标签随机 STAGED 试验
Time-dependent effects of physiology-guided staged complete revascularisation in ST-segment elevation myocardial infarction with MVD disease: a multicentre, open -labelled, randomised STAGED trial
高出血风险患者中使用西罗莫司涂层球囊行 PCI:SELUTION DeNovo 试验证据
Percutaneous coronary intervention using sirolimus eluting balloons in patients at high bleeding risk: Evidence from the SELUTION DeNovo trial
症状发作超 12 小时就诊的临床稳定 STEMI 患者中即刻对比延迟 PCI:LATE-MI 随机试验
Immediate Versus Deferred Percutaneous Coronary Intervention in Clinically Stable Patients with STEMI Presenting Beyond 12 Hours of Symptom Onset - The LATE-MI Randomized Trial
急性心肌梗死 PCI 术后 1 个月停用阿司匹林:TARGET-FIRST 与 ULTIMATE-DAPT 随机试验的个体患者数据汇总分析
Aspirin Discontinuation 1-month After PCI in Acute Myocardial Infarction: Individual-patient-data pooled analysis of the TARGET-FIRST and ULTIMATE-DAPT randomized trials
心肌梗死与再灌注4 场Hot Line 1
LBCS
晚期临床科学:冠状动脉微血管疾病管理
Late-Breaking Clinical Science: management of coronary microvascular disease
维立西呱治疗血管痉挛性心绞痛(ViVA)试验:双盲安慰剂对照随机交叉研究
The Vericiguat in Vasospastic Angina (ViVA) trial: a double-blind placebo-controlled randomized cross-over study
负荷 CMR 对疑似非阻塞性冠脉心肌梗死患者冠脉微血管功能障碍检测的增量诊断价值
Incremental diagnostic value of coronary microvascular dysfunction testing in patients with a working diagnosis of myocardial infarction with nonobstructive coronary arteries by stress CMR
微血管阻力储备与心血管结局:FLOW-CMD 预设分析
Microvascular Resistance Reserve and Cardiovascular Outcomes: Prespecified Analysis of FLOW-CMD
MINOCA 诊断(DOMINO)登记研究:多模态影像的真实世界应用及其对病因分类的影响
The DiagnOsis of MINOCA (DOMINO) registry: a real-world use of multimodality imaging and its impact on etiologic classification
CMR 心外膜脂肪组织鉴别疑似 MINOCA 病因并预测结局
CMR-Derived Epicardial Adipose Tissue Differentiates Etiologies and Predicts Outcomes in Patients With Suspected MINOCA
LBCS
急性冠脉综合征:诊断、危险分层与早期治疗新策略
Acute coronary syndromes: new strategies for diagnosis, risk stratification and early treatment
疑似 ACS 中改良 HEART 评分联合床旁高敏肌钙蛋白 I 分诊:HARTc 2.0 随机试验的临床结局
Modified HEART Score Triage With Point-of-Care hs-cTnI in Suspected ACS: Clinical Outcomes in the HARTc 2.0 Randomized Trial
长肌钙蛋白 T/高敏肌钙蛋白 T 比值作为 Takotsubo 综合征与急性冠脉综合征的新型鉴别指标
The Long-cTnT/hs-cTnT Ratio as a Novel Discriminator Between Takotsubo Syndrome and Acute Coronary Syndrome
基层医疗中基于高敏肌钙蛋白的临床决策规则排除急性冠脉综合征(POB HELP):一项诊断性试验
A Clinical Decision Rule with High-Sensitivity Troponin to Rule Out Acute Coronary Syndrome in Primary Care (POB HELP): A Diagnostic Trial
高危 STEMI 中的缺血预适应:随机多中心 RIP-HIGH 试验
Ischaemic Conditioning in High-Risk ST-elevation Myocardial Infarction: The Randomized, Multicentre, RIP-HIGH Trial
Great Debates
焦点辩论:心梗后射血分数保留患者还应继续使用 β 受体阻滞剂吗
Great Debate: no more beta-blockers for post-myocardial infarction patients with preserved left ventricular ejection fraction
心梗后射血分数保留患者不再使用 β 受体阻滞剂
No more beta-blockers for post-myocardial infarction patients with preserved left ventricular ejection fraction
正方Borja IbanezNational Centre for Cardiovascular Research CNIC AND Fundaci反方Johanne SilvainPitie-Salpetriere Hospital (APHP)评论员Dan AtarOslo University Hospital Ulleval
Hot Line
HOT LINE 4(全球首发专场)
HOT LINE 4
PRESC1SE-MI:ESC 0/1 小时流程的安全性与有效性
PRESC1SE-MI: Safety and efficacy of the ESC 0/1-hour algorithm
心肌梗死中 0/1 小时路径与标准诊疗路径的比较:系统综述与个体患者数据荟萃分析
Performance of 0/1-hour versus standard care pathways in myocardial infarction: a systematic review and IPDMA
AIR-STEMI 试验:STEMI 中的功能性冠脉造影
AIR-STEMI trial: Functional Coronary Angiography in STEMI
TARGET-CTCA——急性胸痛肌钙蛋白指导冠状动脉 CT 血管造影
TARGET-CTCA - Troponin in acute chest pain to guide CTCA
AI 与数字技术1 场
Great Debates
焦点辩论:AI 增强冠脉 CCTA 会在近期取代有创冠脉造影吗
Great Debate: artificial intelligence-enhanced coronary computed tomography angiography will replace invasive coronary angiography in the near future
AI 增强冠脉 CCTA 将在近期取代有创冠脉造影
Artificial intelligence-enhanced coronary computed tomography angiography will replace invasive coronary angiography in the near future
正方Charalambos AntoniadesUniversity of Oxford反方Lorenz RaberSwiss Cardiovascular Center
PCI 策略与腔内影像1 场
Great Debates
焦点辩论:急性冠脉综合征的 PCI 应依据造影还是功能学指导
Great Debate: should percutaneous coronary intervention in acute coronary syndrome be angiography- or physiology-guided?
急性冠脉综合征的 PCI 应由功能学指导
Percutaneous coronary intervention in acute coronary syndrome should be physiology-guided
正方Gianluca CampoUniversity Hospital of Ferrara反方Robert ByrneMater Private Hospital评论员Dawn Louise AdamsonUniversity Hospitals of Coventry and Warwickshire NHS Trust
心脏骤停与危重症1 场Hot Line 1
Hot Line
HOT LINE 12(全球首发专场)
HOT LINE 12
DISCO 试验:复苏成功的院外心脏骤停且无心电图 ST 段抬高患者行急诊冠脉造影
DISCO trial: Acute coronary angiography after resuscitated out-of-hospital cardiac arrest without ST-elevation on the ECG
无 ST 段抬高的院外心脏骤停后的冠脉造影
CAG after OHCA without ST-elevation
HeartRunner 试验:社区第一响应者激活后的院外心脏骤停生存率
The HeartRunner Trial: Out-of-Hospital Cardiac Arrest Survival following Community First Responder activation
布拉格 26 研究:导管引导溶栓治疗肺栓塞
Prague 26: catheter-directed thrombolysis for pulmonary embolism
LAACS-2:外科左心耳封堵 2
LAACS-2. Left Atrial Appendage Closure with Surgery-2
其他1 场
Great Debates
焦点辩论:急性冠脉综合征应常规完全血运重建还是仅处理罪犯血管
Great Debate: routine complete or culprit-only revascularisation for acute coronary syndromes?
所有急性冠脉综合征患者都应常规完全血运重建
All patients with acute coronary syndromes should have routine complete revascularisation
正方Barbara Elisabeth StahliUniversity Hospital Zurich反方Holger ThieleHeart Center Leipzig at University of Leipzig评论员Franz WeidingerLandstrasse Clinic
02中国专家参与场次China Faculty3 场
| 中国专家参与的报告 |
|---|
| 抗栓策略 · 2 项中国专家报告 |
ISOLEDS:远端左主干分叉病变 PCI 中 IVUS 对比 OCT 引导 ISOLEDS: IVUS vs OCT Guidance for PCI of Distal Left Main Bifurcation Lesions |
STEMI 合并多支血管病变中生理学指导的分期完全血运重建的时间依赖性效应:多中心开放标签随机 STAGED 试验 Time-dependent effects of physiology-guided staged complete revascularisation in ST-segment elevation myocardial infarction with MVD disease: a multicentre, open -labelled, randomised STAGED trial |
| 心肌梗死与再灌注 · 1 项中国专家报告 |
CMR 心外膜脂肪组织鉴别疑似 MINOCA 病因并预测结局 CMR-Derived Epicardial Adipose Tissue Differentiates Etiologies and Predicts Outcomes in Patients With Suspected MINOCA |
03本领域中国研究China Abstracts59 篇
| 研究标题 | 第一作者 | 所在机构 |
|---|---|---|
| 流行病学、预后与结局 · 10 篇 | ||
弥合区域差距:中国低GDP地区早发急性冠脉综合征死亡率下降趋势:中国心血管协会(CCA)数据库-胸痛中心的结果 Bridging the regional gap: declining mortality trends in early onset acute coronary syndrome in low GDP region of China: findings from the Chinese Cardiovascular Association (CCA) database-chest pain | Yitian Chen | 首都医科大学附属北京友谊医院 |
收缩压与舒张压和心肌梗死后远期结局的相关性 Association of systolic and diastolic blood pressures with long-term outcomes after myocardial infarction | Wen-Yi Yang | 上海交通大学附属第一人民医院 |
569例川崎病患儿冠状动脉病变的中远期结局与重构 Mid- to long-term outcomes and remodeling of coronary artery lesions in 569 children with kawasaki disease | Bo Han | 山东省立医院 |
Fibrosis-4定义的肝纤维化、传统危险因素与急性冠脉综合征患者心血管事件 Fibrosis-4 –defined liver fibrosis, traditional risk factors, and cardiovascular events in patients with acute coronary syndrome | Xiangyun Kong | 首都医科大学附属北京朝阳医院 |
中国缺血性心脏病负担与护理质量的演变:现状、三十年趋势与2050年预测 The evolving burden and nursing quality of ischemic heart disease in china: current status, three decades of trends, and 2050 forecast | Juwei Dong | 北京中医药大学东直门医院 |
心血管-肾脏-代谢共病与超重及非超重急性心肌梗死患者的死亡风险 Cardiovascular-kidney-metabolic comorbidities and mortality risk in overweight and non‑overweight patients with acute myocardial infarction | Ruiqi Zhang | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
可穿戴同步心音-心电图设备的电机械激活时间预测急性心肌梗死左室收缩功能障碍与预后 ElectroMechanical Activation Time (EMAT) from wearable synchronous phonocardiogram-electrocardiogram device predicts left ventricular systolic dysfunction and prognosis in acute myocardial infarction | Xiaoshu Cheng | 南昌大学第二附属医院 |
基于双能量冠状动脉CT造影预测复发性心绞痛的整合临床-影像组学模型 An integrative clinical-radiomic model for predicting recurrent angina based on dual-energy coronary CT angiography | Wenyi Tang | 中山大学附属第五医院 |
急性冠脉综合征出院后一年内主要不良心血管事件的机器学习风险预测模型 A machine learning-based risk prediction model for major adverse cardiovascular events within one year after discharge in patients with acute coronous syndrome | Tiantian Li | 中国疾病预防控制中心 |
阻塞性睡眠呼吸暂停、胰岛素抵抗与急性冠脉综合征的远期心血管结局 Obstructive sleep apnea, insulin resistance and long-term cardiovascular outcomes in acute coronary syndrome | Feiyu Zhang | 首都医科大学附属北京安贞医院 |
| ST段抬高型心肌梗死 · 8 篇 | ||
STEMI患者的医院水平差异与远期生存:全国队列研究证据 Hospital-level disparities and long-term survival in patients with ST-segment elevation myocardial infarction: evidence from a nationwide cohort study | Feilong Chen | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
18F-FAPI-04 PET/MRI多维度评估冠心病心肌纤维化 Multidimensional assessment of myocardial fibrosis in coronary heart disease using 18F-FAPI-04 PET/MRI | Bo Zhang | 大连医科大学附属第一医院 |
数据驱动识别急性心肌梗死不同亚表型:中国急性心肌梗死注册研究的启示 Data-driven identification of distinct subphenotypes in acute myocardial infarction: insights from the China acute myocardial infarction registry | Zuoxiang Wang | 中国医学科学院北京协和医学院阜外医院 |
卒中诱导的心脏免疫重构可能影响后续心肌梗死的心脏结局 Stroke-induced cardiac immune remodeling may influence cardiac outcomes in subsequent myocardial infarction | Chenyan Liu | 复旦大学附属中山医院 |
酮替芬用于STEMI直接PCI患者的疗效与安全性临床研究 Clinical study on the efficacy and safety of ketotifen in STEMI patients undergoing primary PCI | Pengxin Xie | 北京大学第三医院 |
比伐芦定对比肝素在高出血风险与低出血风险STEMI直接PCI患者中的应用:BRIGHT-4试验预设分析 Bivalirudin versus heparin in high and low bleeding risk patients undergoing primary PCI for STEMI: pre-specified analysis from the BRIGHT-4 trial | Miaohan Qiu | 北部战区总医院 |
罗沙司他早期应用于直接PCI后的STEMI患者:随机临床试验 Early use of roxadustat in patients with ST-segment elevation myocardial infarction after primary percutaneous coronary intervention: a randomised clinical trial | Yueying Wang | 上海交通大学医学院附属瑞金医院 |
造影衍生桡向管壁应变预测急性心肌梗死患者非罪犯血管轻中度病变的血运重建 Angiographically derived radial wall strain predicts revascularization of mild-to-intermediate lesions in non-culprit vessels among patients with acute myocardial infarction | Danbo Lu | 复旦大学附属中山医院 |
| 生物标志物 · 7 篇 | ||
SUA/eGFR比值预测STEMI早期硬事件的优越性:大规模头对头比较与J型风险发现 Superiority of the SUA/eGFR Ratio in predicting early hard events in STEMI: A large-scale head-to-head comparison and J-shaped risk discovery | Kang-Yin Chen | 天津医科大学第二医院 |
C反应蛋白-甘油三酯-葡萄糖指数与意义未明克隆性造血对STEMI患者的预测价值:前瞻性队列研究 The predictive value of C-reactive protein-triglyceride-glucose index and clonal hematopoiesis of indeterminate potential among patients with STEMI---from a prospective cohort study | Xiaoxiao Zhao | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
同型半胱氨酸倍增早发心肌梗死不良结局风险:与肥胖和炎症的协同效应 Homocysteine multiplies risks of adverse outcomes in premature myocardial infarction: synergistic effects with obesity and inflammation | Jing Gao | 天津市胸科医院 |
冠心病鞘脂代谢相关生物标志物鉴定与分子机制研究 Identification of sphingolipid metabolism-related biomarkers and molecular mechanism study in coronary heart disease | Si Wei Chen | 南昌市第三医院 |
支链氨基酸心血管效应的生物学机制:蛋白质组范围孟德尔随机化研究 Biological mechanisms underlying the cardiovascular effects of branch-chain amino acids: a proteome-wide mendelian randomisation study | Jie Zhao | 香港大学 |
即时检测(POCT)与肌钙蛋白在急性胸痛患者中的应用 Utilization of Point-Of-Care Testing (POCT) or troponin in patients with acute chest pain | Hang Long Li | 香港大学 |
生长刺激表达基因2在冠心病患者中的诊断与预后价值 The diagnostic and prognostic value of growth stimulation expressed gene 2 in patients with coronary artery disease | Yang-Yang Qu | 东南大学附属中大医院 |
| 药物治疗 · 5 篇 | ||
养心氏与无既往心血管事件的冠心病患者1年全因死亡的关联 Association between yangxinshi and 1-year all-cause mortality in patients with coronary artery disease without prior cardiovascular events | Kang-Yin Chen | 天津医科大学第二医院 |
院内启动PCSK9抑制剂对急性冠脉综合征远期血脂稳定性影响的因果中介与机器学习分析 Causal mediation and machine learning analysis of in-hospital PCSK9 inhibitor initiation on long-term lipid stability in acute coronary syndrome | Yani Yu | 中国人民解放军总医院 |
阿司匹林对比吲哚布芬治疗NSTEMI患者的一年临床结局:多中心回顾性队列研究 One-year clinical outcomes of aspirin versus indobufen in patients with NSTEMI: a multicenter retrospective cohort study | Hao Zhang | 天津医科大学第二医院 |
他汀初治急性冠脉综合征早期强化联合降脂治疗:真实世界血脂达标与治疗缺口分析 Early intensive combination lipid-lowering therapy in statin-naïve acute coronary syndrome: real-world attainment of lipid targets and analysis of therapeutic gaps | Guang Ming Tan | 香港中文大学 |
血运重建后射血分数保留的ACS患者长期β受体阻滞剂治疗:多中心回顾性队列研究 Long-term beta-blocker therapy after revascularised acute coronary syndrome (ACS) with preserved ejection fraction: a multi-centre retrospective cohort study | Jih Tze Tan | 大林慈济医院 |
| 炎症 · 3 篇 | ||
巨噬细胞FOXK2促进应激性高血糖心肌梗死后的心脏修复 Macrophage FOXK2 promotes cardiac repair in myocardial infarction with stress hyperglycemia | Junguo Jin | 北京大学第一医院 |
局部与全身炎症对冠心病PCI术后血管导向结局的比较影响 Comparative impact of local and systemic inflammation on vessel-oriented outcomes following PCI in coronary artery disease | Zixiang Ye | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
炎症指数显著改善STEMI患者一年死亡预测:大规模多中心研究 Inflammatory indices significantly improve one-year mortality prediction in STEMI patients: a large-scale multi-center study | Kang-Yin Chen | 天津医科大学第二医院 |
| 易损斑块 · 3 篇 | ||
非高胆固醇血症患者中脂蛋白(a)与冠状动脉高危斑块相关吗?OCT影像的启示 Does lipoprotein(a) associate with coronary high-risk plaque in patients without hypercholesterolemia? Insights from optical coherence tomography imaging | Chao Fang | 哈尔滨医科大学附属第二医院 |
冠脉CT造影脂肪衰减指数与斑块特征和OCT识别高危斑块的相关性 Fat attenuation index and plaque characteristics on coronary computed tomography angiography correlation with high-risk plaques identified by optical coherence tomography | Lei Guo | 大连医科大学附属第一医院 |
ApoC3介导PM2.5诱发动脉粥样硬化性心血管疾病的机制 Mechanisms underlying ApoC3-mediated PM2.5-Induced atherosclerotic cardiovascular disease | Yixue Zhao | 北京大学第一医院 |
| 炎症与免疫 · 2 篇 | ||
梗死后抗炎治疗的靶向安全策略:经仿生纳米载体实现心脏限制性NLRP3抑制 A targeted and safe strategy for post-infarction anti-inflammatory therapy: cardiac-restricted NLRP3 inhibition via a biomimetic nanocarrier | Ziqin Zhou | 广东省心血管病研究所 |
冠状动脉粥样硬化新型组织蛋白组学分型识别CAPG为斑块失稳的关键炎症驱动因子 Novel histo-proteomic subtyping of coronary atherosclerosis identifies CAPG as a key inflammatory driver in plaque destabilisation | Xinjie Xu | 国家心血管病中心、阜外医院心血管疾病国家重点实验室 |
| 血栓、血小板与凝血 · 2 篇 | ||
ASIC3激活抑制血栓形成:机体的自我保护机制 Activation of ASIC3 attenuates thrombogenesis: a self-protective mechanism of the body | Peng Zhang | 上海市第九人民医院 |
高血压相关乙酸缺乏经Olfr78增强血小板活化与血栓形成 Hypertension-associated acetate deficiency enhances platelet activation and thrombosis via Olfr78 | Yufei Chen | 华山医院 |
04企业卫星会Industry Symposia7 个系列
赞助商分布3 场 · Medtronic 1 场 · Chiesi 1 场 · Zentiva 1 场 · Novo Nordisk 1 场 · Amgen
炎症与残余风险2 个系列
Zentiva
为心血管炎症降温:2026 年有哪些治疗选择
Cooling the fire of cardiovascular inflammation: what are the treatment options in 2026?
欢迎与介绍
Welcome and introduction
炎症作为动脉粥样硬化的治疗靶点:我们对残余炎症与可用治疗了解多少?
Inflammation as a therapeutic target in atherosclerosis: what do we know about residual inflammation and available treatments?
动脉粥样硬化性心血管疾病患者的炎症减轻
Inflammation reduction in patients with atherosclerotic cardiovascular disease
治疗谁、何时治疗:从临床研究与指南到临床实践——讨论
Whom to treat and when to treat: from clinical studies and guidelines to clinical practice - discussion
Novo Nordisk
心血管炎症:受审的沉默杀手
Cardiovascular inflammation: the silent killer on trial
欢迎与介绍
Welcome and introductions
心血管炎症的视角
Perspectives on cardiovascular inflammation
心血管炎症的患病率
The prevalence of cardiovascular inflammation
心血管炎症领域不断演进的临床指南
Evolving clinical guidelines in cardiovascular inflammation
总结与闭幕
Summary and close
心脏骤停与危重症1 个系列
Chiesi
快速起效、精准可控:静脉 P2Y12 抑制剂在 CCS、ACS 与心源性休克中的角色演进
Rapid power, precise control: the evolving role of intravenous P2Y12 inhibition in chronic coronary syndromes, acute coronary syndromes, and cardiogenic shock
开幕致辞
Opening address
急性冠脉综合征挑战:PCI 中速度优先
The acute coronary syndrome challenge: speed as a priority in PCI
慢性冠脉综合征中静脉抗血小板治疗的个体化
Tailoring IV antiplatelet therapy in chronic coronary syndromes
休克因素:优化抗血小板治疗
The shock factor: optimising antiplatelet therapy
快速起效、精准控制:静脉 P2Y12 抑制在慢性冠脉综合征、急性冠脉综合征和心源性休克中不断演变的作用——讨论与问答
Rapid power, precise control: the evolving role of intravenous P2Y12 inhibition in chronic coronary syndromes, acute coronary syndromes, and cardiogenic shock - discussion and Q&A
PCI 策略与腔内影像1 个系列
Medtronic
冠脉生理学新标准:基于造影的 FFR 及其临床决策价值
The new standard in coronary physiology: angio‑based FFR and its role in clinical decision-making
冠脉生理学的新标准:基于血管造影的 FFR 及其在临床决策中的作用
The new standard in coronary physiology: angio‑based FFR and its role in clinical decision-making
降脂新药(PCSK9/Lp(a))1 个系列
Amgen
冠心病 LDL-C 管理:是否应该从导管室开始
Low-density lipoprotein cholesterol management in coronary artery disease: should it begin in the cath lab?
欢迎与学习目标
Welcome and learning objectives
从急性冠脉综合征到早期血脂干预:ARMYDA 及更多研究的经验
From acute coronary syndrome to early lipid intervention: lessons from ARMYDA and beyond
斑块影像教给我们关于早期强化降低 LDL-C 的什么知识
What plaque imaging teaches us about early intensive low-density lipoprotein cholesterol lowering
AMUNDSEN 试验结果:早期低密度脂蛋白胆固醇管理的当代证据
AMUNDSEN Trial results: contemporary evidence for early low-density lipoprotein cholesterol management
EVOLVE-MI 与真实世界证据:从试验信号到体系变革
EVOLVE-MI and real-world evidence: from trial signal to system change
专家讨论:LDL-C 管理是否应从导管室开始?
Panel discussion: should low-density lipoprotein cholesterol management begin in the cath lab?
综合与其他2 个系列
Medtronic
TAVI 入门:早期识别与转诊要点
Introduction to TAVI: essentials for early recognition and referral
TAVI 入门:早期识别与转诊要点
Introduction to TAVI: essentials for early recognition and referral
Medtronic
TAVI 患者旅程:从首次识别到专科转诊
The TAVI patient journey: from first identification to specialist referral
TAVI 患者之旅:从首次识别到专科转诊
The TAVI patient journey: from first identification to specialist referral
企业卫星会内容由赞助方支持,此处仅作学术日程信息陈列,不代表编辑立场。